Nutriband Inc. - $NTRB STOCK NEWS

Nutriband (NASDAQ:NTRB), a developer of transdermal pharmaceuticals and technology, will host an exclusive live investor webinar on May 30, 2024, at 4:15 p.m. ET.

Organized by RedChip Companies, the event will feature Chairman Serguei Melnik and CEO Gareth Sheridan, who will provide insights into the company's current operations and future milestones.

Investors can register for the free webinar and submit questions beforehand or during the live session.

Nutriband announced the appointment of Sergei Glinka to its board of directors. Glinka, an experienced business leader, brings a wealth of experience from his roles in major European companies. The Glinka family has invested $4.5 million in Nutriband via a private placement in April 2024, which totaled $8.4 million. Nutriband aims to use these funds to complete the FDA approval process for its AVERSA™ technology. AVERSA™, currently patented in 45 countries, is projected to reach peak annual US sales between $80 million and $200 million. The global opioid market was valued at $22.8 billion in 2022.

RedChip Companies will air interviews with Can-Fite BioPharma (NYSE American:CANF) and Nutriband Inc. (NASDAQ:NTRB) on the RedChip Small Stocks, Big Money™ show on Bloomberg TV. Pnina Fishman, Executive Chairperson and Chief Scientific Officer of Can-Fite BioPharma, discusses the company's advanced clinical stage drug development focusing on oncology and inflammatory diseases. Can-Fite has two drug candidates in advanced stages of development with registration plans agreed with the U.S. FDA and the EMA. Gareth Sheridan, Founder and CEO of Nutriband, talks about their AVERSA™ abuse-deterrent transdermal technology to address the global opioid crisis. Nutriband's lead product, AVERSA™ Fentanyl, is targeting peak annual sales of $80 million to $200 million.

Nutriband Inc. announced the closing of an $8.4 million private placement to fund the commercial development of AVERSA Fentanyl, an abuse-deterrent opioid patch. The company aims to reach peak annual US sales of $80 million to $200 million. Nutriband is working with Kindeva Drug Delivery to develop the commercial manufacturing process for the product. The development milestones include FDA IND filing, pivotal human abuse potential clinical study, and NDA filing. The company targets Q1 of 2025 for NDA submission. Nutriband's AVERSA technology shows promising abuse-deterrent properties in preliminary studies. The company plans to file a 505(b)(2) NDA based on a single Phase 1 human abuse potential clinical study, potentially receiving expedited FDA review. Nutriband's pipeline includes abuse deterrent versions of fentanyl, buprenorphine, and methylphenidate transdermal patches.

Nutriband Inc. has signed an exclusive supplier agreement with Fit For Life Group, a major brand license holder, for the launch of a new product under one of their top brands. The agreement was fully executed on April 19, 2024. Nutriband's subsidiary, Active Intelligence, will serve as the manufacturer. Fit For Life Group, founded in 2016, is a prominent player in the fitness equipment and yoga accessories market, with a strong brand portfolio including Gaiam, Reebok, Adidas, New Balance, SPRI, and FILA. They target a wide range of consumers from beginners to professionals, with distribution through major retailers like Target, Walmart, Dick's Sporting Goods, and Amazon.

Nutriband Inc. has announced an $8.4M private placement to fund the development of AVERSA™ Fentanyl and target FDA approval in Q1 2025. The company has entered into securities purchase agreements for the sale of 2,100,000 shares of common stock at $4 per share, with investors receiving warrants to purchase additional shares at $6.43 per share.

Nutriband Inc. announces engagement with Fit For Life Group, a major brand license holder, for manufacturing innovative products. Fit For Life Group, a market leader in fitness equipment and yoga accessories, has partnered with Nutriband to create innovative products for a wide range of consumers.

Nutriband Inc. announces the development of AVERSA™ Fentanyl, an abuse-deterrent fentanyl transdermal patch, through a 505(b)(2) New Drug Application (NDA) pathway. Partnering with Kindeva Drug Delivery, Nutriband aims to revolutionize the opioid market by incorporating their AVERSA™ technology into FDA-approved transdermal fentanyl patches. The NDA submission will be based on a single Phase 1 human abuse potential clinical study, eliminating the need for Phase 2 or 3 trials. This streamlined regulatory process could lead to expedited FDA review, potentially making AVERSA™ Fentanyl the first abuse-deterrent patch approved globally. Market analysis projects peak annual US sales of $80 million to $200 million for AVERSA™ Fentanyl, tapping into the $22.8 billion global opioid market.

Nutriband Inc. presents data on transdermal patch abuse and accidental pediatric exposure at the 2024 AAPM Annual Meeting. The company's AVERSA™ technology aims to provide safer abuse-deterrent transdermal patches for opioid and stimulant drugs, addressing a critical unmet need in the market.